← Back to patent-cliff list
Mazindol Extended Release (NLS)
Tier C — Watch / tradeMazindol Extended Release (NLS)
Nls Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DAT, NET
Brand：Quilience, Nolazol
Indications (approved)：发作性睡病, 过度嗜睡
Regional status
US
Phase II
2021-09-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mazindol Extended Release (NLS)?
Approved indications include: 发作性睡病, 过度嗜睡.
When does the Mazindol Extended Release (NLS) patent expire?
No public expiry year is available for Mazindol Extended Release (NLS) yet; this page updates once verified.
How do I get a quote for Mazindol Extended Release (NLS) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06